首页 > 最新文献

Clinical and Experimental Gastroenterology最新文献

英文 中文
Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer. 局部晚期胰腺癌的立体定向体放射治疗
IF 2.5 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-16 eCollection Date: 2024-01-01 DOI: 10.2147/CEG.S341189
Shane S Neibart, Shalini Moningi, Krishan R Jethwa

Introduction: For patients with locally advanced pancreatic cancer (LAPC), who are candidates for radiation therapy, dose-escalated radiation therapy (RT) offers unique benefits over traditional radiation techniques. In this review, we present a historical perspective of dose-escalated RT for LAPC. We also outline advances in SBRT delivery, one form of dose escalation and a framework for selecting patients for treatment with SBRT.

Results: Techniques for delivering SBRT to patients with LAPC have evolved considerably, now allowing for dose-escalation and superior respiratory motion management. At the same time, advancements in systemic therapy, particularly the use of induction multiagent chemotherapy, have called into question which patients would benefit most from radiation therapy. Multidisciplinary assessment of patients with LAPC is critical to guide management and select patients for local therapy. Results from ongoing trials will establish if there is a role of dose-escalated SBRT after induction chemotherapy for carefully selected patients.

Conclusion: Patients with LAPC have more therapeutic options than ever before. Careful selection for SBRT may enhance patient outcomes, pending the maturation of pivotal clinical trials.

简介:对于适合接受放射治疗的局部晚期胰腺癌(LAPC)患者,剂量递增放射治疗(RT)与传统放射技术相比具有独特的优势。在本综述中,我们将从历史角度介绍剂量递增 RT 治疗局部晚期胰腺癌的情况。我们还概述了 SBRT 放射治疗的进展、剂量升级的一种形式以及选择患者接受 SBRT 治疗的框架:结果:为LAPC患者提供SBRT的技术已经有了很大的发展,现在可以实现剂量升级和出色的呼吸运动管理。与此同时,全身治疗的进步,尤其是诱导多试剂化疗的使用,使人们对哪些患者能从放疗中获益最大产生了疑问。对 LAPC 患者进行多学科评估对于指导治疗和选择接受局部治疗的患者至关重要。正在进行的试验结果将确定,在诱导化疗后,经过仔细筛选的患者是否可以接受剂量递增的SBRT治疗:结论:LAPC 患者拥有比以往更多的治疗选择。结论:LAPC 患者拥有比以往更多的治疗选择,在关键性临床试验成熟之前,谨慎选择 SBRT 可提高患者的治疗效果。
{"title":"Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer.","authors":"Shane S Neibart, Shalini Moningi, Krishan R Jethwa","doi":"10.2147/CEG.S341189","DOIUrl":"https://doi.org/10.2147/CEG.S341189","url":null,"abstract":"<p><strong>Introduction: </strong>For patients with locally advanced pancreatic cancer (LAPC), who are candidates for radiation therapy, dose-escalated radiation therapy (RT) offers unique benefits over traditional radiation techniques. In this review, we present a historical perspective of dose-escalated RT for LAPC. We also outline advances in SBRT delivery, one form of dose escalation and a framework for selecting patients for treatment with SBRT.</p><p><strong>Results: </strong>Techniques for delivering SBRT to patients with LAPC have evolved considerably, now allowing for dose-escalation and superior respiratory motion management. At the same time, advancements in systemic therapy, particularly the use of induction multiagent chemotherapy, have called into question which patients would benefit most from radiation therapy. Multidisciplinary assessment of patients with LAPC is critical to guide management and select patients for local therapy. Results from ongoing trials will establish if there is a role of dose-escalated SBRT after induction chemotherapy for carefully selected patients.</p><p><strong>Conclusion: </strong>Patients with LAPC have more therapeutic options than ever before. Careful selection for SBRT may enhance patient outcomes, pending the maturation of pivotal clinical trials.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"17 ","pages":"213-225"},"PeriodicalIF":2.5,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming Geographical Constraints: A Diagnostic and Therapeutic Challenge of Amebic Liver Abscess in a Non-Endemic Region. 克服地域限制:非流行地区阿米巴肝脓肿的诊断和治疗挑战。
IF 2.5 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-09 eCollection Date: 2024-01-01 DOI: 10.2147/CEG.S459696
Bogusz Aksak-Wąs, Malwina Karasińska-Cieślak, Miłosz Parczewski

This case report provides data on unique challenges related to amoebiasis diagnostics and treatment in non-endemic regions. The presented case report is focused a 28-year-old male patient of Indian origin, temporarily living in Poland, who was diagnosed with an amoebic liver abscess. The patient presented with a range of non-specific symptoms including shortness of breath, chest pain, and fever. The differential diagnosis included cardio-pulmonary diseases, a range of tropical diseases such as malaria or typhoid fever, bacterial abscesses, and malignancies, necessitating a comprehensive, multi-modal diagnostic approach. This approach included an extensive review of patient history, physical examination, and various laboratory and imaging investigations. A further challenge in this case was the unavailability of standard cysticidal treatments in Poland, which required individualized therapeutic strategy. Despite these obstacles, the patient was successfully treated using an alternative regimen of intravenous metronidazole, ceftriaxone, doxycycline, chloroquine, and finally, trimethoprim/sulfamethoxazole (treatment with metronidazole was used as a base drug, due to the lack of typical cysticidal treatment, an alternative treatment was added: chloroquine is a recommended drug used in the treatment of pregnant patients, in addition, doxycycline showed in vitro activity against Entamoeba histolytica). This therapeutic journey underscored the value of adaptability in treatment protocols, particularly in regions where certain resources may not be readily available. This case report underlines the importance of broadening the differential diagnosis in non-endemic regions to include tropical diseases, particularly in the context of increasing global travel and migration. It also highlights the significance of employing comprehensive diagnostic strategies and adaptable treatment protocols in such scenarios. In addition, the report reiterates the need for global collaboration and education among healthcare providers to effectively manage tropical diseases, especially in non-endemic regions. Through its exploration of the complexities associated with diagnosing and managing amebiasis in a non-endemic region, this report offers valuable insights to clinicians worldwide.

本病例报告提供了非流行地区阿米巴病诊断和治疗所面临的独特挑战的相关数据。本病例报告的重点是一名暂居波兰的 28 岁印度裔男性患者,他被诊断出患有阿米巴肝脓肿。患者出现一系列非特异性症状,包括气短、胸痛和发热。鉴别诊断包括心肺疾病、一系列热带疾病(如疟疾或伤寒)、细菌性脓肿和恶性肿瘤,因此有必要采取全面、多模式的诊断方法。这种方法包括对患者病史、体格检查以及各种实验室和影像学检查的广泛回顾。该病例面临的另一个挑战是波兰没有标准的囊肿治疗方法,因此需要采取个性化的治疗策略。尽管存在这些障碍,该患者还是成功地接受了由甲硝唑、头孢曲松、强力霉素、氯喹和三甲双胍/磺胺甲噁唑组成的替代治疗方案(甲硝唑治疗是基础药物,由于缺乏典型的杀囊肿治疗药物,因此增加了一种替代治疗药物:氯喹是一种推荐用于治疗妊娠患者的药物,此外,强力霉素在体外对恩塔莫阿米巴组织溶解菌有活性)。这一治疗历程凸显了治疗方案适应性的价值,尤其是在某些资源可能不易获得的地区。本病例报告强调了在非流行病地区扩大鉴别诊断范围以包括热带疾病的重要性,尤其是在全球旅行和移民日益增多的情况下。报告还强调了在这种情况下采用综合诊断策略和适应性治疗方案的重要性。此外,报告还重申,医疗服务提供者之间需要开展全球合作和教育,以有效管理热带疾病,尤其是在非流行地区。本报告通过探讨在非流行地区诊断和管理阿米巴病的复杂性,为全球临床医生提供了宝贵的见解。
{"title":"Overcoming Geographical Constraints: A Diagnostic and Therapeutic Challenge of Amebic Liver Abscess in a Non-Endemic Region.","authors":"Bogusz Aksak-Wąs, Malwina Karasińska-Cieślak, Miłosz Parczewski","doi":"10.2147/CEG.S459696","DOIUrl":"10.2147/CEG.S459696","url":null,"abstract":"<p><p>This case report provides data on unique challenges related to amoebiasis diagnostics and treatment in non-endemic regions. The presented case report is focused a 28-year-old male patient of Indian origin, temporarily living in Poland, who was diagnosed with an amoebic liver abscess. The patient presented with a range of non-specific symptoms including shortness of breath, chest pain, and fever. The differential diagnosis included cardio-pulmonary diseases, a range of tropical diseases such as malaria or typhoid fever, bacterial abscesses, and malignancies, necessitating a comprehensive, multi-modal diagnostic approach. This approach included an extensive review of patient history, physical examination, and various laboratory and imaging investigations. A further challenge in this case was the unavailability of standard cysticidal treatments in Poland, which required individualized therapeutic strategy. Despite these obstacles, the patient was successfully treated using an alternative regimen of intravenous metronidazole, ceftriaxone, doxycycline, chloroquine, and finally, trimethoprim/sulfamethoxazole (treatment with metronidazole was used as a base drug, due to the lack of typical cysticidal treatment, an alternative treatment was added: chloroquine is a recommended drug used in the treatment of pregnant patients, in addition, doxycycline showed in vitro activity against Entamoeba histolytica). This therapeutic journey underscored the value of adaptability in treatment protocols, particularly in regions where certain resources may not be readily available. This case report underlines the importance of broadening the differential diagnosis in non-endemic regions to include tropical diseases, particularly in the context of increasing global travel and migration. It also highlights the significance of employing comprehensive diagnostic strategies and adaptable treatment protocols in such scenarios. In addition, the report reiterates the need for global collaboration and education among healthcare providers to effectively manage tropical diseases, especially in non-endemic regions. Through its exploration of the complexities associated with diagnosing and managing amebiasis in a non-endemic region, this report offers valuable insights to clinicians worldwide.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"17 ","pages":"185-190"},"PeriodicalIF":2.5,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11246073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 (NHE3). 肠道渗透性、伴有便秘的肠易激综合征以及钠-氢交换异构体 3 (NHE3) 的作用。
IF 2.4 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-06-06 eCollection Date: 2024-01-01 DOI: 10.2147/CEG.S455101
Brian E Lacy, David Rosenbaum, Susan Edelstein, Kenji Kozuka, Laura A Williams, David C Kunkel

Increased intestinal permeability has been identified as one of the many pathophysiological factors associated with the development of irritable bowel syndrome (IBS), a common disorder of gut-brain interaction. The layer of epithelial cells that lines the intestine is permeable to a limited degree, and the amount of paracellular permeability is tightly controlled to enable the absorption of ions, nutrients, and water from the lumen. Increased intestinal permeability to macromolecules can be triggered by a variety of insults, including infections, toxins from food poisoning, or allergens, which in turn cause an inflammatory response and are associated with abdominal pain in patients with IBS. This review article discusses increased intestinal permeability in IBS, focusing on IBS with constipation (IBS-C) through the lens of a patient case with a reported prior diagnosis of "leaky gut syndrome" upon initial contact with a gastrointestinal specialist. We review advantages and disadvantages of several methods of measuring intestinal permeability in patients and discuss when measuring intestinal permeability is appropriate in the therapeutic journey of patients with IBS-C. Furthermore, we discuss a possible mechanism of restoring the intestinal barrier to its healthy state through altering intracellular pH by inhibiting sodium-hydrogen exchanger isoform 3 (NHE3). Tenapanor is a minimally absorbed, small-molecule inhibitor of NHE3 that has been approved by the US Food and Drug Administration for the treatment of IBS-C in adults. Preclinical studies showed that tenapanor may restore the intestinal barrier in IBS-C by affecting the conformation of tight junction proteins via NHE3 inhibition to block the paracellular transport of macromolecules from the intestinal lumen. Testing for increased permeability in patients with IBS-C who experience abdominal pain may help inform the choice of therapeutics and alter patients' misconceptions about "leaky gut syndrome".

肠道通透性增加已被确定为与肠易激综合征(IBS)发病有关的众多病理生理因素之一,肠易激综合征是一种常见的肠道与大脑相互作用紊乱的疾病。肠道上皮细胞层的通透性是有限的,细胞旁通透性的量受到严格控制,以保证肠腔中离子、营养物质和水分的吸收。感染、食物中毒产生的毒素或过敏原等各种损伤都可能导致肠道对大分子的通透性增加,进而引起炎症反应,并与肠易激综合征患者的腹痛有关。这篇综述文章讨论了肠道渗透性增加在肠易激综合征(IBS)中的作用,通过一个病人的病例,重点讨论了伴有便秘的肠易激综合征(IBS-C),据报道该病人在与胃肠专科医生初次接触时就被诊断为 "肠漏综合征"。我们回顾了几种测量患者肠道通透性方法的优缺点,并讨论了在 IBS-C 患者的治疗过程中何时适合测量肠道通透性。此外,我们还讨论了通过抑制钠-氢交换异构体 3(NHE3)来改变细胞内 pH 值,从而将肠道屏障恢复到健康状态的可能机制。Tenapanor 是一种吸收率极低的 NHE3 小分子抑制剂,已被美国食品药品管理局批准用于治疗成人肠易激综合征。临床前研究表明,替那帕诺可通过抑制 NHE3 影响紧密连接蛋白的构象,阻止肠腔内大分子的旁细胞转运,从而恢复 IBS-C 的肠道屏障。对有腹痛症状的 IBS-C 患者进行通透性增加测试,有助于为治疗方法的选择提供依据,并改变患者对 "肠漏综合征 "的误解。
{"title":"Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 (NHE3).","authors":"Brian E Lacy, David Rosenbaum, Susan Edelstein, Kenji Kozuka, Laura A Williams, David C Kunkel","doi":"10.2147/CEG.S455101","DOIUrl":"10.2147/CEG.S455101","url":null,"abstract":"<p><p>Increased intestinal permeability has been identified as one of the many pathophysiological factors associated with the development of irritable bowel syndrome (IBS), a common disorder of gut-brain interaction. The layer of epithelial cells that lines the intestine is permeable to a limited degree, and the amount of paracellular permeability is tightly controlled to enable the absorption of ions, nutrients, and water from the lumen. Increased intestinal permeability to macromolecules can be triggered by a variety of insults, including infections, toxins from food poisoning, or allergens, which in turn cause an inflammatory response and are associated with abdominal pain in patients with IBS. This review article discusses increased intestinal permeability in IBS, focusing on IBS with constipation (IBS-C) through the lens of a patient case with a reported prior diagnosis of \"leaky gut syndrome\" upon initial contact with a gastrointestinal specialist. We review advantages and disadvantages of several methods of measuring intestinal permeability in patients and discuss when measuring intestinal permeability is appropriate in the therapeutic journey of patients with IBS-C. Furthermore, we discuss a possible mechanism of restoring the intestinal barrier to its healthy state through altering intracellular pH by inhibiting sodium-hydrogen exchanger isoform 3 (NHE3). Tenapanor is a minimally absorbed, small-molecule inhibitor of NHE3 that has been approved by the US Food and Drug Administration for the treatment of IBS-C in adults. Preclinical studies showed that tenapanor may restore the intestinal barrier in IBS-C by affecting the conformation of tight junction proteins via NHE3 inhibition to block the paracellular transport of macromolecules from the intestinal lumen. Testing for increased permeability in patients with IBS-C who experience abdominal pain may help inform the choice of therapeutics and alter patients' misconceptions about \"leaky gut syndrome\".</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"17 ","pages":"173-183"},"PeriodicalIF":2.4,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bowel Habits, Obesity, Intestinal Microbiota and Their Influence on Hemorrhoidal Disease: a Mendelian Randomization Study. 排便习惯、肥胖、肠道微生物群及其对痔疮疾病的影响:孟德尔随机研究。
IF 2.4 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-10 eCollection Date: 2024-01-01 DOI: 10.2147/CEG.S450807
Miaozhi Yu, Yuan Shang, Lingling Han, Xi Yu

Purpose: Hemorrhoids (HEM) are the most common perianal disease, but current observational studies have yielded inconsistent results in investigating the risk factors. Our further exploration of the risk factors will help prevent the disease.

Patients and methods: We conducted a two-sample bidirectional Mendelian randomization (MR) analysis using publicly available genome-wide association studies (GWAS) statistics from multiple consortia. The inverse-variance weighted (IVW) method was used for the primary analysis. We applied four complementary methods, including weighted median, weighted mode, MR-Egger regression, and Cochrane's Q value, to detect and correct the effects of horizontal pleiotropy.

Results: Genetically determined constipation (OR = 0.97, 95% CI: 0.91-1.03, P = 0.28) and diarrhea (OR = 1.00, 95% CI: 0.99-1.01, P = 0.90) did not have a causal effect on HEM but stool frequency (OR = 1.28, 95% CI: 1.05-1.55, P = 0.01), waist-to-hip ratio adjusted for BMI (OR = 1.11, 95% CI: 1.06-1.64, P = 1.59×10-5), and order Burkholderiales (OR = 1.09, 95% CI = 1.04-1.14, p = 1.63×10-4) had a causal effect on. Furthermore, we found a significant causal effect of constipation on HEM in the reverse MR analysis (OR = 1.21, 95% CI: 1.13-1.28, P = 3.72×10-9). The results of MR-Egger regression, Weighted Median, and Weighted Mode methods were consistent with those of the IVW method. Horizontal pleiotropy was unlikely to distort the causal estimates, as indicated by the sensitivity analysis.

Conclusion: Our MR analysis reveals a causal association between stool frequency and waist-to-hip ratio with HEM, despite variations in results reported by observational studies. Unexpectedly, we found a relationship between the order Burkholderiales in the gut flora and HEM, although the mechanism is unclear.

目的:痔疮(HEM)是最常见的肛周疾病,但目前的观察性研究在调查风险因素方面的结果并不一致。我们对风险因素的进一步探索将有助于预防该疾病:我们利用多个联盟公开提供的全基因组关联研究(GWAS)统计数据,进行了双样本双向孟德尔随机化(MR)分析。主要分析采用了逆方差加权(IVW)方法。我们采用了四种补充方法,包括加权中位数、加权模式、MR-Egger 回归和 Cochrane's Q 值,以检测和校正水平多效性的影响:基因决定的便秘(OR = 0.97,95% CI:0.91-1.03,P = 0.28)和腹泻(OR = 1.00,95% CI:0.99-1.01,P = 0.90)对 HEM 没有因果影响,但大便频率(OR = 1.28,95% CI:1.05-1.55,P = 0.01)、根据体重指数调整后的腰臀比(OR = 1.11,95% CI:1.06-1.64,P = 1.59×10-5)和伯克氏目(OR = 1.09,95% CI = 1.04-1.14,P = 1.63×10-4)对 HEM 有因果关系。此外,在反向 MR 分析中,我们发现便秘对 HEM 有明显的因果效应(OR = 1.21,95% CI:1.13-1.28,P = 3.72×10-9)。MR-Egger回归法、加权中值法和加权模式法的结果与IVW法的结果一致。敏感性分析表明,水平多效性不太可能扭曲因果关系估计值:我们的磁共振分析揭示了大便次数和腰臀比与 HEM 之间的因果关系,尽管观察性研究报告的结果各不相同。意想不到的是,我们发现肠道菌群中的伯克霍尔德氏菌目与 HEM 之间存在关系,尽管其机制尚不清楚。
{"title":"Bowel Habits, Obesity, Intestinal Microbiota and Their Influence on Hemorrhoidal Disease: a Mendelian Randomization Study.","authors":"Miaozhi Yu, Yuan Shang, Lingling Han, Xi Yu","doi":"10.2147/CEG.S450807","DOIUrl":"10.2147/CEG.S450807","url":null,"abstract":"<p><strong>Purpose: </strong>Hemorrhoids (HEM) are the most common perianal disease, but current observational studies have yielded inconsistent results in investigating the risk factors. Our further exploration of the risk factors will help prevent the disease.</p><p><strong>Patients and methods: </strong>We conducted a two-sample bidirectional Mendelian randomization (MR) analysis using publicly available genome-wide association studies (GWAS) statistics from multiple consortia. The inverse-variance weighted (IVW) method was used for the primary analysis. We applied four complementary methods, including weighted median, weighted mode, MR-Egger regression, and Cochrane's Q value, to detect and correct the effects of horizontal pleiotropy.</p><p><strong>Results: </strong>Genetically determined constipation (OR = 0.97, 95% CI: 0.91-1.03, P = 0.28) and diarrhea (OR = 1.00, 95% CI: 0.99-1.01, P = 0.90) did not have a causal effect on HEM but stool frequency (OR = 1.28, 95% CI: 1.05-1.55, P = 0.01), waist-to-hip ratio adjusted for BMI (OR = 1.11, 95% CI: 1.06-1.64, P = 1.59×10-5), and order Burkholderiales (OR = 1.09, 95% CI = 1.04-1.14, p = 1.63×10-4) had a causal effect on. Furthermore, we found a significant causal effect of constipation on HEM in the reverse MR analysis (OR = 1.21, 95% CI: 1.13-1.28, P = 3.72×10-9). The results of MR-Egger regression, Weighted Median, and Weighted Mode methods were consistent with those of the IVW method. Horizontal pleiotropy was unlikely to distort the causal estimates, as indicated by the sensitivity analysis.</p><p><strong>Conclusion: </strong>Our MR analysis reveals a causal association between stool frequency and waist-to-hip ratio with HEM, despite variations in results reported by observational studies. Unexpectedly, we found a relationship between the order Burkholderiales in the gut flora and HEM, although the mechanism is unclear.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"17 ","pages":"157-164"},"PeriodicalIF":2.4,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should an Incidental Meckel Diverticulum Be Resected? A Systematic Review. 偶发梅克尔憩室应否切除?系统回顾。
IF 2.4 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-07 eCollection Date: 2024-01-01 DOI: 10.2147/CEG.S460053
Vipul D Yagnik, Pankaj Garg, Sushil Dawka

Background: Meckel Diverticulum [MD), a common congenital anomaly of the gastrointestinal tract, poses a dilemma when incidentally encountered during surgery. Despite historical descriptions and known complications of symptomatic MD, the decision to resect an incidental MD (IMD) lacks clear guidelines. This study aims to assess whether resecting IMDs is justified by synthesizing evidence from studies published between 2000 and 2023. Factors influencing this decision, such as demographic risks, surgical advancements and complications, are systematically examined.

Methods and material: Following the PRISMA 2020 guidelines, this review incorporates 42 eligible studies with data on outcomes of asymptomatic MD management. Studies, both favoring and opposing resection, were analyzed.

Results: Considering complications, malignancy potential, and operative safety, the risk-benefit analysis presents a nuanced picture. Some authors propose conditional resection based on specific criteria, emphasizing patient-specific factors. Of 2934 cases analyzed for short- and long-term complications, the morbidity rate was 5.69%. Of 571 cases where mortality data were available, all 5 fatalities were attributed to the primary disease rather than IMD resection.

Conclusion: The sporadic, unpredictable presentation of IMD and the variability of both the primary disease and the patient make formulation of definitive guidelines challenging. The non-uniformity of complications reporting underscores the need for standardized categorization. While the balance of evidence leans towards resection of IMDs, this study acknowledges the individualized nature of this decision. Increased safety in surgery and anesthesia, along with better understanding and management of complications favor a judicious preference for resection, while taking into account patient characteristics and the primary disease.

背景:梅克尔憩室(MD)是一种常见的先天性胃肠道畸形,在手术中偶然发现时会让人进退两难。尽管历史上对无症状的梅克尔憩室(MD)有过描述并已知其并发症,但对是否切除偶发的梅克尔憩室(IMD)缺乏明确的指导原则。本研究旨在通过综合 2000 年至 2023 年间发表的研究证据,评估是否有理由切除偶发性多发性肠梗阻。系统研究了影响这一决定的因素,如人口统计学风险、手术进展和并发症:根据 PRISMA 2020 指南,本综述纳入了 42 项符合条件的研究,这些研究提供了有关无症状 MD 管理结果的数据。分析了赞成和反对切除的研究:考虑到并发症、恶性肿瘤的可能性和手术安全性,风险-效益分析呈现出一种微妙的情况。一些学者根据特定标准提出了有条件的切除术,强调了患者的特定因素。在 2934 例短期和长期并发症分析病例中,发病率为 5.69%。在有死亡数据的 571 例病例中,所有 5 例死亡均归因于原发疾病而非 IMD 切除术:结论:IMD 的表现零星、难以预测,而且原发疾病和患者的情况各不相同,因此制定明确的指南具有挑战性。并发症报告的不统一性凸显了标准化分类的必要性。虽然证据的天平倾向于切除 IMD,但本研究承认这一决定的个体化性质。手术和麻醉安全性的提高,以及对并发症的更好理解和处理,都有利于在考虑患者特征和原发疾病的情况下明智地选择切除术。
{"title":"Should an Incidental Meckel Diverticulum Be Resected? A Systematic Review.","authors":"Vipul D Yagnik, Pankaj Garg, Sushil Dawka","doi":"10.2147/CEG.S460053","DOIUrl":"10.2147/CEG.S460053","url":null,"abstract":"<p><strong>Background: </strong>Meckel Diverticulum [MD), a common congenital anomaly of the gastrointestinal tract, poses a dilemma when incidentally encountered during surgery. Despite historical descriptions and known complications of symptomatic MD, the decision to resect an incidental MD (IMD) lacks clear guidelines. This study aims to assess whether resecting IMDs is justified by synthesizing evidence from studies published between 2000 and 2023. Factors influencing this decision, such as demographic risks, surgical advancements and complications, are systematically examined.</p><p><strong>Methods and material: </strong>Following the PRISMA 2020 guidelines, this review incorporates 42 eligible studies with data on outcomes of asymptomatic MD management. Studies, both favoring and opposing resection, were analyzed.</p><p><strong>Results: </strong>Considering complications, malignancy potential, and operative safety, the risk-benefit analysis presents a nuanced picture. Some authors propose conditional resection based on specific criteria, emphasizing patient-specific factors. Of 2934 cases analyzed for short- and long-term complications, the morbidity rate was 5.69%. Of 571 cases where mortality data were available, all 5 fatalities were attributed to the primary disease rather than IMD resection.</p><p><strong>Conclusion: </strong>The sporadic, unpredictable presentation of IMD and the variability of both the primary disease and the patient make formulation of definitive guidelines challenging. The non-uniformity of complications reporting underscores the need for standardized categorization. While the balance of evidence leans towards resection of IMDs, this study acknowledges the individualized nature of this decision. Increased safety in surgery and anesthesia, along with better understanding and management of complications favor a judicious preference for resection, while taking into account patient characteristics and the primary disease.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"17 ","pages":"147-155"},"PeriodicalIF":2.4,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11088382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Necrotizing Pancreatitis Complicated with Paroxysmal Nocturnal Haemoglobinuria: A Case Report. 急性坏死性胰腺炎并发阵发性夜间血红蛋白尿:病例报告。
IF 2.4 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-29 eCollection Date: 2024-01-01 DOI: 10.2147/CEG.S449594
Mengbo Xiao, Ying Di, Yu An, Yunfeng Cui

This report presents a unique case of acute necrotizing pancreatitis(ANP) concomitant with paroxysmal nocturnal hemoglobinuria(PNH), a combination that has not been documented in existing literature. The impact of PNH on ANP and its treatment remains uncertain due to the lack of consensus. The case described herein involves a patient who exhibited both ANP and PNH, subsequently experiencing splanchnic vein thrombosis (SVT), resulting in substantial intra-abdominal and gastrointestinal hemorrhaging. We attempted to analyze the role of PNH in the formation of SVT in ANP and propose some new insights and hypotheses for the treatment of such patients.

本报告介绍了一例独特的急性坏死性胰腺炎(ANP)并发阵发性夜间血红蛋白尿(PNH)的病例,现有文献中还没有关于这种并发症的记载。由于缺乏共识,PNH 对 ANP 及其治疗的影响仍不确定。本文描述的病例中,一名患者同时表现出 ANP 和 PNH,随后出现脾静脉血栓形成(SVT),导致腹腔和胃肠道大量出血。我们试图分析 PNH 在 ANP 患者 SVT 形成过程中的作用,并为此类患者的治疗提出一些新的见解和假设。
{"title":"Acute Necrotizing Pancreatitis Complicated with Paroxysmal Nocturnal Haemoglobinuria: A Case Report.","authors":"Mengbo Xiao, Ying Di, Yu An, Yunfeng Cui","doi":"10.2147/CEG.S449594","DOIUrl":"https://doi.org/10.2147/CEG.S449594","url":null,"abstract":"<p><p>This report presents a unique case of acute necrotizing pancreatitis(ANP) concomitant with paroxysmal nocturnal hemoglobinuria(PNH), a combination that has not been documented in existing literature. The impact of PNH on ANP and its treatment remains uncertain due to the lack of consensus. The case described herein involves a patient who exhibited both ANP and PNH, subsequently experiencing splanchnic vein thrombosis (SVT), resulting in substantial intra-abdominal and gastrointestinal hemorrhaging. We attempted to analyze the role of PNH in the formation of SVT in ANP and propose some new insights and hypotheses for the treatment of such patients.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"17 ","pages":"141-145"},"PeriodicalIF":2.4,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11067917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Jejunal Ectopic Pancreatic Tissue Rest as Lead Point in Patients with Intussusception: A Rare Case Report and Review of Literature. 作为肠套叠患者导引点的空肠异位胰腺组织息肉:罕见病例报告和文献综述。
IF 2.4 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-29 eCollection Date: 2024-01-01 DOI: 10.2147/CEG.S425986
Worku Mekonnen Sefefe, Destaw Biadgie Tesfaw, Andualem Dagne Tebikew, Assefa Sisay Ayenew, Bereket Amare Dencha, Temesgen Agegnehu Abebe

Background: Ectopic pancreas (EP), characterized by pancreatic tissue outside its usual location, poses diagnostic challenges due to its asymptomatic nature in most cases. Gastric lesions are often symptomatic, causing epigastric pain or gastric outlet obstruction. Rarely, jejunal lesions can lead to intestinal obstruction or intussusception. The elusive preoperative diagnosis lacks specific biochemical markers, relying on intraoperative biopsy and histopathology as gold standards.

Case presentation: We present a unique case of a 37-year-old female with 12-hour crampy abdominal pain, bilious vomiting, blood-mixed diarrhea, abdominal distension, and obstructive symptoms. Imaging revealed jejunojejunal intussusception with a jejunal mass as the lead point. Intraoperatively, also identified jejunal mass as lead point. Resection of mass and end-to-end jejunojejunal anastomosis were performed, resulting in a successful outcome. Histopathological examination identified a type I ectopic pancreas within the muscularis propria. Twelve months postoperatively, the patient exhibited no stricture or recurrence.

Conclusion: Ectopic pancreas, with varied symptoms, poses diagnostic hurdles. Despite the diagnostic challenges, surgical excision remains the optimal treatment for symptomatic cases. This report contributes to the limited literature on ectopic pancreas, emphasizing the importance of considering this entity in the differential diagnosis of gastrointestinal pathology.

背景:异位胰腺(EP)的特点是胰腺组织超出其正常位置,由于大多数病例无症状,因此给诊断带来了挑战。胃部病变通常无症状,会引起上腹痛或胃出口梗阻。空肠病变可导致肠梗阻或肠套叠,这种情况较为罕见。难以捉摸的术前诊断缺乏特异性生化指标,只能依靠术中活检和组织病理学作为金标准:我们介绍了一例独特的病例:37 岁女性,腹痛 12 小时,伴有胆汁性呕吐、血性混合性腹泻、腹胀和梗阻症状。影像学检查发现空肠空肠肠套叠,空肠肿块为先导点。术中也发现空肠肿块为前导点。手术切除了肿块并进行了空肠端端吻合术,最终取得了成功。组织病理学检查发现固有肌内有一个 I 型异位胰腺。术后 12 个月,患者未出现狭窄或复发:结论:异位胰腺症状多样,给诊断带来了困难。结论:异位胰腺的症状多种多样,给诊断带来了困难。尽管诊断困难重重,但手术切除仍是无症状病例的最佳治疗方法。本报告为有关异位胰腺的有限文献做出了贡献,强调了在胃肠道病理鉴别诊断中考虑这一实体的重要性。
{"title":"Jejunal Ectopic Pancreatic Tissue Rest as Lead Point in Patients with Intussusception: A Rare Case Report and Review of Literature.","authors":"Worku Mekonnen Sefefe, Destaw Biadgie Tesfaw, Andualem Dagne Tebikew, Assefa Sisay Ayenew, Bereket Amare Dencha, Temesgen Agegnehu Abebe","doi":"10.2147/CEG.S425986","DOIUrl":"https://doi.org/10.2147/CEG.S425986","url":null,"abstract":"<p><strong>Background: </strong>Ectopic pancreas (EP), characterized by pancreatic tissue outside its usual location, poses diagnostic challenges due to its asymptomatic nature in most cases. Gastric lesions are often symptomatic, causing epigastric pain or gastric outlet obstruction. Rarely, jejunal lesions can lead to intestinal obstruction or intussusception. The elusive preoperative diagnosis lacks specific biochemical markers, relying on intraoperative biopsy and histopathology as gold standards.</p><p><strong>Case presentation: </strong>We present a unique case of a 37-year-old female with 12-hour crampy abdominal pain, bilious vomiting, blood-mixed diarrhea, abdominal distension, and obstructive symptoms. Imaging revealed jejunojejunal intussusception with a jejunal mass as the lead point. Intraoperatively, also identified jejunal mass as lead point. Resection of mass and end-to-end jejunojejunal anastomosis were performed, resulting in a successful outcome. Histopathological examination identified a type I ectopic pancreas within the muscularis propria. Twelve months postoperatively, the patient exhibited no stricture or recurrence.</p><p><strong>Conclusion: </strong>Ectopic pancreas, with varied symptoms, poses diagnostic hurdles. Despite the diagnostic challenges, surgical excision remains the optimal treatment for symptomatic cases. This report contributes to the limited literature on ectopic pancreas, emphasizing the importance of considering this entity in the differential diagnosis of gastrointestinal pathology.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"17 ","pages":"135-139"},"PeriodicalIF":2.4,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11067941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Systematic Review: Fecal Bacterial Profile in Patients with Irritable Bowel Syndrome Analyzed with the GA-Map Dysbiosis Test Based on the 16S rRNA Gene of Bacterial Species or Groups. 系统性综述:基于细菌物种或菌群的 16S rRNA 基因的 GA-Map 菌群失调测试分析肠易激综合征患者的粪便细菌谱。
IF 2.4 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-04-17 eCollection Date: 2024-01-01 DOI: 10.2147/CEG.S451675
Erica Sande Teige, Urd Sortvik, Gülen Arslan Lied

Purpose: The diagnosis of irritable bowel syndrome (IBS) is based on symptom-based criteria due to lack of reliable disease-specific biomarkers. Gut microbiota is perturbed in IBS and when comparing different methods used to analyze gut microbiota, the results might be obscured. Therefore, in this systematic review we aimed to investigate the profile of fecal bacterial markers and dysbiosis index (DI) in patients with IBS and IBS subgroups compared to healthy controls (HCs) conducted by the same method (GA-map Dysbiosis Test based on16S rRNA sequencing).

Material and method: We searched PubMed, EMBASE (Ovid) and Cochrane Library for case-control studies comparing fecal gut microbiota analyzed with the GA-map® Dysbiosis Test (Oslo, Norway) in patients with IBS and HCs. Our outcomes were the difference in fecal bacterial markers and DI in patients with IBS and IBS subgroups compared to HCs.

Results: The search identified 28 citations; five articles were included. Most studies evaluated fecal bacterial markers and DI in patients with diarrhea-predominant IBS (IBS-D). Results of fecal bacteria profile in IBS and IBS subgroups compared to HCs are inconsistent, however, two studies showed increased levels of Ruminococcus gnavus in IBS-D compared to HCs and results of DI indicated IBS and IBS subgroups (especially IBS-D) having higher DI compared to HCs.

Conclusion: This systematic review revealed inconsistent findings in respect to differences in bacterial markers between IBS and IBS subgroups with HCs in studies using the GA-map Dysbiosis Test based on 16S rRNA sequencing. However, the test is quite novel, and few studies have used the method so far. More research comparing fecal microbiota profile differences in IBS and IBS subgroups compared to HCs utilizing the same method of analysis is needed to give us further insight into the gut bacteria profile in IBS and the clinical consequences of intestinal dysbiosis.

目的:由于缺乏可靠的疾病特异性生物标志物,肠易激综合征(IBS)的诊断以症状为标准。肠易激综合征患者的肠道微生物群受到干扰,在比较用于分析肠道微生物群的不同方法时,结果可能会模糊不清。因此,在这篇系统性综述中,我们旨在通过相同的方法(基于16S rRNA测序的GA-map菌群失调测试),研究肠易激综合征患者和肠易激综合征亚组与健康对照组(HCs)相比,其粪便细菌标记物和菌群失调指数(DI)的概况:我们检索了 PubMed、EMBASE (Ovid) 和 Cochrane 图书馆的病例对照研究,比较了用 GA-map® Dysbiosis Test(挪威奥斯陆)分析的肠易激综合征患者和健康对照者的粪便肠道微生物群。我们的研究结果是肠易激综合征患者和肠易激综合征亚组患者的粪便细菌标记物和DI与肠易激综合征患者和肠易激综合征亚组患者的粪便细菌标记物和DI的差异:结果:搜索发现了 28 篇引文,其中包括 5 篇文章。大多数研究评估了以腹泻为主的 IBS(IBS-D)患者的粪便细菌标记物和 DI。然而,有两项研究显示,与普通人相比,IBS-D 患者的反刍球菌含量增加,而 DI 的结果表明,与普通人相比,IBS 和 IBS 亚组(尤其是 IBS-D)的 DI 较高:本系统综述显示,在使用基于 16S rRNA 测序的 GA-map 菌群失调测试的研究中,IBS 和 IBS 亚组与 HCs 之间细菌标记物的差异结果不一致。然而,该检测方法非常新颖,迄今为止使用该方法的研究很少。我们需要进行更多的研究,利用相同的分析方法比较 IBS 和 IBS 亚群与 HCs 的粪便微生物群谱差异,从而进一步了解 IBS 的肠道细菌谱以及肠道菌群失调的临床后果。
{"title":"A Systematic Review: Fecal Bacterial Profile in Patients with Irritable Bowel Syndrome Analyzed with the GA-Map Dysbiosis Test Based on the 16S rRNA Gene of Bacterial Species or Groups.","authors":"Erica Sande Teige, Urd Sortvik, Gülen Arslan Lied","doi":"10.2147/CEG.S451675","DOIUrl":"https://doi.org/10.2147/CEG.S451675","url":null,"abstract":"<p><strong>Purpose: </strong>The diagnosis of irritable bowel syndrome (IBS) is based on symptom-based criteria due to lack of reliable disease-specific biomarkers. Gut microbiota is perturbed in IBS and when comparing different methods used to analyze gut microbiota, the results might be obscured. Therefore, in this systematic review we aimed to investigate the profile of fecal bacterial markers and dysbiosis index (DI) in patients with IBS and IBS subgroups compared to healthy controls (HCs) conducted by the same method (GA-map Dysbiosis Test based on16S rRNA sequencing).</p><p><strong>Material and method: </strong>We searched PubMed, EMBASE (Ovid) and Cochrane Library for case-control studies comparing fecal gut microbiota analyzed with the GA-map<sup>®</sup> Dysbiosis Test (Oslo, Norway) in patients with IBS and HCs. Our outcomes were the difference in fecal bacterial markers and DI in patients with IBS and IBS subgroups compared to HCs.</p><p><strong>Results: </strong>The search identified 28 citations; five articles were included. Most studies evaluated fecal bacterial markers and DI in patients with diarrhea-predominant IBS (IBS-D). Results of fecal bacteria profile in IBS and IBS subgroups compared to HCs are inconsistent, however, two studies showed increased levels of <i>Ruminococcus gnavus</i> in IBS-D compared to HCs and results of DI indicated IBS and IBS subgroups (especially IBS-D) having higher DI compared to HCs.</p><p><strong>Conclusion: </strong>This systematic review revealed inconsistent findings in respect to differences in bacterial markers between IBS and IBS subgroups with HCs in studies using the GA-map Dysbiosis Test based on 16S rRNA sequencing. However, the test is quite novel, and few studies have used the method so far. More research comparing fecal microbiota profile differences in IBS and IBS subgroups compared to HCs utilizing the same method of analysis is needed to give us further insight into the gut bacteria profile in IBS and the clinical consequences of intestinal dysbiosis.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"17 ","pages":"109-120"},"PeriodicalIF":2.4,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11032674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal Management of Refractory Crohn's Disease: Current Landscape and Future Direction. 难治性克罗恩病的优化治疗:当前形势与未来方向。
IF 2.4 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-03-26 eCollection Date: 2024-01-01 DOI: 10.2147/CEG.S359376
Kate E Lee, Violet Y Tu, Adam S Faye

Refractory Crohn's disease, defined as ongoing inflammation despite the trial of multiple advanced therapies, impacts a number of individuals with Crohn's disease, and leads to significant burden in quality of life and cost. Interventions such as early implementation of advanced therapies, optimization of current therapies prior to switching to an alternative, as well as understanding the overlapping pathophysiology between immune-mediated disorders, however, can help shift the current landscape and reduce the number of patients with refractory disease. As such, in this review we summarize the key takeaways of the latest research in the management of moderate-to-severe Crohn's disease, focusing on maximization of our currently available medications, while also exploring topics such as combination advanced therapies. We also describe evidence for emerging and alternative therapeutic modalities, including fecal microbiota transplant, exclusive enteral feeding, hyperbaric oxygen, stem cell therapy, bone marrow transplant, and posaconazole, with a focus on both the potential impact and specific indications for each.

难治性克罗恩病的定义是,尽管试用了多种先进疗法,但炎症仍在持续,它影响着许多克罗恩病患者,并导致生活质量和费用方面的重大负担。然而,早期实施先进疗法、在转用替代疗法之前优化当前疗法以及了解免疫介导疾病之间重叠的病理生理学等干预措施有助于改变目前的状况,减少难治性疾病患者的数量。因此,在本综述中,我们总结了治疗中重度克罗恩病的最新研究成果,重点是最大限度地利用现有药物,同时还探讨了联合先进疗法等主题。我们还介绍了新出现的替代治疗方法的证据,包括粪便微生物群移植、纯肠道喂养、高压氧、干细胞疗法、骨髓移植和泊沙康唑,重点介绍了每种方法的潜在影响和具体适应症。
{"title":"Optimal Management of Refractory Crohn's Disease: Current Landscape and Future Direction.","authors":"Kate E Lee, Violet Y Tu, Adam S Faye","doi":"10.2147/CEG.S359376","DOIUrl":"10.2147/CEG.S359376","url":null,"abstract":"<p><p>Refractory Crohn's disease, defined as ongoing inflammation despite the trial of multiple advanced therapies, impacts a number of individuals with Crohn's disease, and leads to significant burden in quality of life and cost. Interventions such as early implementation of advanced therapies, optimization of current therapies prior to switching to an alternative, as well as understanding the overlapping pathophysiology between immune-mediated disorders, however, can help shift the current landscape and reduce the number of patients with refractory disease. As such, in this review we summarize the key takeaways of the latest research in the management of moderate-to-severe Crohn's disease, focusing on maximization of our currently available medications, while also exploring topics such as combination advanced therapies. We also describe evidence for emerging and alternative therapeutic modalities, including fecal microbiota transplant, exclusive enteral feeding, hyperbaric oxygen, stem cell therapy, bone marrow transplant, and posaconazole, with a focus on both the potential impact and specific indications for each.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"17 ","pages":"75-86"},"PeriodicalIF":2.4,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140334893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TCHH as a Novel Prognostic Biomarker for Patients with Gastric Cancer by Bioinformatics Analysis. 通过生物信息学分析将TCHH作为胃癌患者的新型预后生物标记物
IF 2.4 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-26 eCollection Date: 2024-01-01 DOI: 10.2147/CEG.S451676
Fu Yu, Li Xia Zhao, Shangqi Chu

Background: This study aims to investigate the clinicopathological significance and prognostic value of Trichohyalin (TCHH) in gastric cancer patients through bioinformatics analysis.

Materials and methods: Data on TCHH expression and clinicopathological information were sourced from The Cancer Genome Atlas (TCGA). The Wilcoxon signed-rank test was used for evaluating the correlation between TCHH mRNA expression levels and clinicopathological features. The predictive significance of TCHH mRNA expression for overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in patients with gastric cancer was assessed using Cox regression models. Furthermore, measures of immune cell infiltration in gastric cancer were made, and studies of gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment were also carried out to investigate the possible roles of TCHH in patients with gastric cancer.

Results: Compared to normal tissues, gastric cancer had a considerably higher expression of TCHH mRNA (P < 0.05). Wilcoxon analysis revealed a significant association between TCHH mRNA expression and the pathologic M stage (P = 0.017). High TPMT mRNA levels were also correlated with worse OS, DFS, and PFI in gastric cancer patients (both P < 0.05). TCHH showed significant negative correlations with the levels of NK CD56dim infiltration (r = -0.157, p = 0.002), Th17 cells infiltration (r = -0.235, P < 0.001), and Th2 infiltration (r = -0.195, P < 0.001). Furthermore, enrichment analysis indicated potential involvement in intermediate filament cytoskeleton organization, DNA methylation in gamete generation, cell-cell recognition, and G protein-coupled peptide receptor (GPCRs) activity.

Conclusion: The level of TCHH mRNA may serve as a novel prognostic biomarker for gastric cancer patients.

背景:本研究旨在通过生物信息学分析,探讨胃癌患者中三叶胆碱(TCHH)的临床病理意义和预后价值:本研究旨在通过生物信息学分析,探讨胃癌患者中三叶胆碱(Trichohyalin,TCHH)的临床病理学意义和预后价值:TCHH表达数据和临床病理信息来自癌症基因组图谱(TCGA)。采用Wilcoxon符号秩检验评估TCHH mRNA表达水平与临床病理特征之间的相关性。利用Cox回归模型评估了TCHH mRNA表达对胃癌患者总生存期(OS)、疾病特异性生存期(DSS)和无进展间期(PFI)的预测意义。此外,还对胃癌中的免疫细胞浸润进行了测量,并对基因本体(GO)和京都基因与基因组百科全书(KEGG)进行了富集研究,以探讨TCHH在胃癌患者中的可能作用:结果:与正常组织相比,胃癌的 TCHH mRNA 表达量明显更高(P < 0.05)。Wilcoxon分析显示,TCHH mRNA表达与病理M分期有显著关联(P = 0.017)。高 TPMT mRNA 水平也与胃癌患者较差的 OS、DFS 和 PFI 相关(均 P <0.05)。TCHH与NK CD56dim浸润水平(r = -0.157,P = 0.002)、Th17细胞浸润水平(r = -0.235,P < 0.001)和Th2细胞浸润水平(r = -0.195,P < 0.001)呈明显负相关。此外,富集分析表明,TCHH可能参与了中间丝细胞骨架组织、配子生成过程中的DNA甲基化、细胞-细胞识别和G蛋白偶联肽受体(GPCRs)活性:结论:TCHH mRNA水平可作为胃癌患者的一种新型预后生物标志物。
{"title":"TCHH as a Novel Prognostic Biomarker for Patients with Gastric Cancer by Bioinformatics Analysis.","authors":"Fu Yu, Li Xia Zhao, Shangqi Chu","doi":"10.2147/CEG.S451676","DOIUrl":"10.2147/CEG.S451676","url":null,"abstract":"<p><strong>Background: </strong>This study aims to investigate the clinicopathological significance and prognostic value of Trichohyalin (TCHH) in gastric cancer patients through bioinformatics analysis.</p><p><strong>Materials and methods: </strong>Data on TCHH expression and clinicopathological information were sourced from The Cancer Genome Atlas (TCGA). The Wilcoxon signed-rank test was used for evaluating the correlation between TCHH mRNA expression levels and clinicopathological features. The predictive significance of TCHH mRNA expression for overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in patients with gastric cancer was assessed using Cox regression models. Furthermore, measures of immune cell infiltration in gastric cancer were made, and studies of gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment were also carried out to investigate the possible roles of TCHH in patients with gastric cancer.</p><p><strong>Results: </strong>Compared to normal tissues, gastric cancer had a considerably higher expression of TCHH mRNA (P < 0.05). Wilcoxon analysis revealed a significant association between TCHH mRNA expression and the pathologic M stage (P = 0.017). High TPMT mRNA levels were also correlated with worse OS, DFS, and PFI in gastric cancer patients (both P < 0.05). TCHH showed significant negative correlations with the levels of NK CD56dim infiltration (r = -0.157, p = 0.002), Th17 cells infiltration (r = -0.235, P < 0.001), and Th2 infiltration (r = -0.195, P < 0.001). Furthermore, enrichment analysis indicated potential involvement in intermediate filament cytoskeleton organization, DNA methylation in gamete generation, cell-cell recognition, and G protein-coupled peptide receptor (GPCRs) activity.</p><p><strong>Conclusion: </strong>The level of TCHH mRNA may serve as a novel prognostic biomarker for gastric cancer patients.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"17 ","pages":"61-74"},"PeriodicalIF":2.4,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Experimental Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1